GoodRx Holdings
GDRXNASDAQUSD
- — Source valuation snapshot. Not a live recalculation.
- — Latest filed annual earnings; price snapshot date unavailable. Not forward P/E.
- — Diluted earnings per share from the latest filed annual.
- $3.65 Prior regular-session close from the quote source.
- $3.45–$3.64 Regular-session low and high so far today.
- 977.3K Regular-session shares traded · Nov 10, 4:00 PM ET.
- Not yet confirmed The company has not confirmed its next report date. Reported quarters are available in the chart’s Earnings view.
- $1.77–$3.89 52-week trading low and high returned by the quote source.
Understand the Business
Why the Stock Moved
Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.
The core investment thesis
Own GDRX if its consumer drug-savings marketplace remains a necessary traffic source for PBMs, pharmacies, and manufacturers, but the stock depends on proving that this mature platform can defend partner economics and cash flow despite slow revenue.
GDRX price history
Loading recent earnings…
INVESTMENT THESIS
What must happen next
U.S. prescription-price opacity and out-of-pocket pain keep GoodRx's consumer savings marketplace relevant enough to protect partner-funded transaction demand.HoldingMateriality: High
GAAP annual revenue was $796.9 million in FY2025 versus $745.4 million in FY2021, showing the platform remained monetizable over the period provided. If consumer intent stays with GoodRx, the company has a monetizable demand source; if consumers migrate elsewhere, partner revenue follows.
Watch: Amazon Pharmacy or RxPass becomes the default cash-pay search destination for common prescriptions, reducing GoodRx consumer intent before reported revenue weakens.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual revenue was $796.9 million in FY2025 versus $745.4 million in FY2021, showing the platform remained monetizable over the.
Open source ↗GoodRx retains economics only if PBMs, pharmacies, and manufacturers keep treating its traffic as incremental prescription volume or patient acquisition rather than margin leakage.StrengtheningMateriality: High
GAAP annual operating income improved from a $27.0 million loss in FY2023 to $65.8 million in FY2024 and $87.5 million in FY2025. Partner acceptance and economics determine whether consumer traffic converts into profitable revenue instead of becoming a low-value referral commodity.
Watch: A major PBM such as CVS Caremark, Express Scripts, or OptumRx reprices, restricts, or terminates GoodRx coupon economics.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual operating income improved from a $27.0 million loss in FY2023 to $65.8 million in FY2024 and $87.5 million.
Open source ↗The digital marketplace can create value from slow growth if management keeps customer acquisition, product, and compliance spending below the incremental monetization of prescription and pharma-solution traffic.StrengtheningMateriality: Medium
GAAP annual operating income rose to $87.5 million in FY2025 from $65.8 million in FY2024 and a $27.0 million loss in FY2023. With revenue growth muted, operating leverage is the main path from a useful platform to per-share value creation.
Watch: Google search changes, app-store distribution shifts, or paid-search competition force GoodRx to spend materially more to acquire the same prescription shoppers.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual operating income rose to $87.5 million in FY2025 from $65.8 million in FY2024 and a $27.0 million loss.
Open source ↗GoodRx's marketplace economics should fund the business internally only if management does not have to buy growth through large acquisitions, consumer incentives, or unfavorable working-capital concessions.HoldingMateriality: Medium
GAAP annual operating cash flow has been positive in each year shown: $146.8 million in FY2022, $138.3 million in FY2023, $183.9 million in FY2024, and $167.9 million in FY2025. Durable operating cash flow gives owners downside protection and capital-allocation options; cash-consuming growth would weaken the thesis.
Watch: GoodRx must subsidize prescription prices, increase consumer incentives, or materially raise marketing spend to defend traffic.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual operating cash flow has been positive in each year shown: $146.8 million in FY2022, $138.3 million in FY2023.
Open source ↗The thesis has room to play out only while liquidity remains ample enough to absorb partner shocks and invest in product without distressed financing.HoldingMateriality: Medium
Cash was $261.8 million at FY2025 year-end. A strong liquidity position lets GoodRx handle contract disruption or competitive investment; shrinking liquidity would reduce strategic flexibility.
Watch: Debt refinancing, litigation, regulatory settlements, or partner disputes consume cash before revenue growth returns.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Cash was $261.8 million at FY2025 year-end.
Open source ↗
Full investment case & evidence
Loading the original research archive…
Original research
U.S. prescription-price opacity and out-of-pocket pain keep GoodRx's consumer savings marketplace relevant enough to protect partner-funded transaction demand. If consumer intent stays with GoodRx, the company has a monetizable demand source; if consumers migrate elsewhere, partner revenue follows.
GoodRx retains economics only if PBMs, pharmacies, and manufacturers keep treating its traffic as incremental prescription volume or patient acquisition rather than margin leakage. Partner acceptance and economics determine whether consumer traffic converts into profitable revenue instead of becoming a low-value referral commodity.
The digital marketplace can create value from slow growth if management keeps customer acquisition, product, and compliance spending below the incremental monetization of prescription and pharma-solution traffic. With revenue growth muted, operating leverage is the main path from a useful platform to per-share value creation.
GoodRx's marketplace economics should fund the business internally only if management does not have to buy growth through large acquisitions, consumer incentives, or unfavorable working-capital concessions. Durable operating cash flow gives owners downside protection and capital-allocation options; cash-consuming growth would weaken the thesis.
The thesis has room to play out only while liquidity remains ample enough to absorb partner shocks and invest in product without distressed financing. A strong liquidity position lets GoodRx handle contract disruption or competitive investment; shrinking liquidity would reduce strategic flexibility.
All standing thesis claims
Original report summary
its consumer drug-savings marketplace remains a necessary traffic source for PBMs, pharmacies, and manufacturers, but the stock depends on proving that this mature platform can defend partner economics and cash flow despite slow revenue.
BULL CASE / BEAR CASE
Bull case and bear case for GoodRx Holdings
Where the evidence on GoodRx Holdings stands: Holding on the latest evidence (Nov 7, 2026). Of its 5 thesis points, 2 strengthening and 3 holding.
Bull case: what the evidence supports
U.S. prescription-price opacity and out-of-pocket pain keep GoodRx's consumer savings marketplace relevant enough to protect partner-funded transaction demand.
GoodRx retains economics only if PBMs, pharmacies, and manufacturers keep treating its traffic as incremental prescription volume or patient acquisition rather than margin leakage.
The digital marketplace can create value from slow growth if management keeps customer acquisition, product, and compliance spending below the incremental monetization of prescription and pharma-solution traffic.
GoodRx's marketplace economics should fund the business internally only if management does not have to buy growth through large acquisitions, consumer incentives, or unfavorable working-capital concessions.
The thesis has room to play out only while liquidity remains ample enough to absorb partner shocks and invest in product without distressed financing.
Bear case: what would count against it
Amazon Pharmacy or RxPass becomes the default cash-pay search destination for common prescriptions, reducing GoodRx consumer intent before reported revenue weakens.
A major PBM such as CVS Caremark, Express Scripts, or OptumRx reprices, restricts, or terminates GoodRx coupon economics.
Google search changes, app-store distribution shifts, or paid-search competition force GoodRx to spend materially more to acquire the same prescription shoppers.
Thesis-Break Engine
What has broken in GoodRx Holdings’s thesis
Each break OptimistFi flagged on GoodRx Holdings, dated — with what has historically followed the same kind of break across the market, not a forecast for GoodRx Holdings.
- Late SEC filingcondition set before this filing
Across all companies, this kind of break has happened 4,811 times before. Those stocks trailed comparable companies by a median of 12% over the next six months, and 52% of them trailed it by 10 points or more.
- Financial restatementcondition set before this filing
Across all companies, this kind of break has happened 793 times before. Those stocks trailed comparable companies by a median of 5% over the next six months, and 44% of them trailed it by 10 points or more.
Several kinds of break have stacked on GoodRx Holdings at once. A cluster is a stronger read than any one signal alone.
MARKET + FINANCIAL SNAPSHOT
The numbers behind the thesis
What Changed
- MIXEDPreviously issued financials no longer reliable (restatement).
GoodRx Holdings filed an SEC 8-K on 2026-11-02: Previously issued financials no longer reliable (restatement). It is a dated development that tests the current thesis.
- MIXEDDirector or principal officer change.
GoodRx Holdings filed an SEC 8-K on 2026-08-05: Director or principal officer change. It is a dated development that tests the current thesis.
- MIXEDReported results of operations (earnings release).
GoodRx Holdings filed an SEC 8-K on 2026-08-05: Reported results of operations (earnings release). It is a dated development that tests the current thesis.
RISKS / FALSIFIERS
What could break the thesis
- Amazon Pharmacy or RxPass becomes the default cash-pay search destination for common prescriptions, reducing GoodRx consumer intent before reported revenue weakens.
- A major PBM such as CVS Caremark, Express Scripts, or OptumRx reprices, restricts, or terminates GoodRx coupon economics.
- Google search changes, app-store distribution shifts, or paid-search competition force GoodRx to spend materially more to acquire the same prescription shoppers.
- GoodRx must subsidize prescription prices, increase consumer incentives, or materially raise marketing spend to defend traffic.
- Debt refinancing, litigation, regulatory settlements, or partner disputes consume cash before revenue growth returns.
GDRX news
Loading headlines…
FINANCIAL STATEMENTS
GDRX income statement
Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.
GDRX: quick answers
- When does GoodRx Holdings (GDRX) report earnings next?
- GoodRx Holdings's next results were projected for November 3, 2026, from the dates of its own results filings with the SEC, and it has not filed them yet. It last reported on August 5, 2026. Earnings calendar
- What is GDRX's short interest?
- As of October 30, 2026, 3.6M GDRX shares were sold short, down 2.7% from the count before. At the stock's average daily volume that is 3.0 days to cover. FINRA publishes the count twice a month. GDRX short interest history
- Have members of Congress traded GDRX?
- 1 trade in GDRX has been disclosed under the STOCK Act by members of Congress, the President or senior officials, none in reports made public in the last 90 days. Every disclosed GDRX trade